Brokerages expect Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating) to announce earnings per share of ($0.21) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Viking Therapeutics’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.24). Viking Therapeutics reported earnings of ($0.20) per share in the same quarter last year, which would suggest a negative year over year growth rate of 5%. The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Viking Therapeutics will report full year earnings of ($0.90) per share for the current year, with EPS estimates ranging from ($1.03) to ($0.78). For the next financial year, analysts anticipate that the business will post earnings of ($1.07) per share, with EPS estimates ranging from ($1.45) to ($0.70). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that cover Viking Therapeutics.
Viking Therapeutics (NASDAQ:VKTX – Get Rating) last posted its quarterly earnings data on Wednesday, April 27th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). During the same quarter last year, the company posted ($0.19) EPS.
Shares of VKTX opened at $2.27 on Friday. The firm has a market capitalization of $175.64 million, a P/E ratio of -3.07 and a beta of 1.73. Viking Therapeutics has a 12-month low of $2.15 and a 12-month high of $7.20. The firm has a fifty day moving average price of $2.76 and a 200-day moving average price of $3.93.
Large investors have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC lifted its stake in Viking Therapeutics by 1,062.8% in the fourth quarter. Lindbrook Capital LLC now owns 7,500 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 6,855 shares during the period. Engineers Gate Manager LP purchased a new stake in shares of Viking Therapeutics during the first quarter valued at about $37,000. Point72 Hong Kong Ltd purchased a new stake in shares of Viking Therapeutics during the fourth quarter valued at about $38,000. Qube Research & Technologies Ltd purchased a new stake in shares of Viking Therapeutics during the fourth quarter valued at about $51,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Viking Therapeutics during the fourth quarter valued at about $52,000. 46.74% of the stock is owned by institutional investors.
Viking Therapeutics Company Profile (Get Rating)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
- Get a free copy of the StockNews.com research report on Viking Therapeutics (VKTX)
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
- Silicon Labs Stock is Falling to a Better Place
- The Institutional Tide Has Turned For Cisco Systems
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.